Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Meeting Results for: June 25, 2008

Drug Name Review Type Committee Recommendation Prior Approval Status � Final Determination
Duac CS New Drug Initial Review Require Prior Approval Prior Approval Required
Evoclin Foam New Drug Initial Review Require Prior Approval Prior Approval Required
Glumetza New Drug Initial Review Require Prior Approval Prior Approval Required
Cimzia New Drug Initial Review Require Prior Approval Prior Approval Required
Pristiq New Drug Initial Review Require Prior Approval Prior Approval Required
Treximet New Drug Initial Review Require Prior Approval Prior Approval Required
Bystolic New Drug Initial Review Removed from Agenda Prior Approval Required
Luvox CR New Drug Initial Review Require Prior Approval Prior Approval Required
Voltaren Gel New Drug Initial Review Require Prior Approval Prior Approval Required
Iquix New Drug Appeal Remove Prior Approval Requirement Prior Approval requirement removed
Sanctura XR New Drug Appeal Require Prior Approval Prior Approval Required
Vyvanse New Drug Appeal Require Prior Approval Prior Approval Required
Combigan New Drug Appeal Remove Prior Approval Requirement Prior Approval requirement removed
Vusion New Drug Appeal Require Prior Approval Prior Approval Required
Strattera PDL Appeal Remove Prior Approval Requirement Prior Approval Required
Lovaza PDL Appeal Require Prior Approval Prior Approval Required
Fazaclo PDL Appeal Remove Prior Approval Requirement Prior Approval requirement removed